Log in
Enquire now
‌

US Patent 9212225 Bispecific CD33 and CD3 binding proteins

Patent 9212225 was granted and assigned to Amphivena Therapeutics on December, 2015 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent

Patent attributes

Patent Applicant
Amphivena Therapeutics
Amphivena Therapeutics
Current Assignee
Amphivena Therapeutics
Amphivena Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9212225
Date of Patent
December 15, 2015
Patent Application Number
14642497
Date Filed
March 9, 2015
Patent Citations Received
‌
US Patent 11859010 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
3
‌
US Patent 11753469 Methods of using bispecific CD33 and CD3 binding proteins
Patent Primary Examiner
‌
Lynn Bristol
Patent abstract

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9212225 Bispecific CD33 and CD3 binding proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.